We’ve recently updated our valuation analysis.

Prothena Valuation

Is 0Y3M undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0Y3M?

Other financial metrics that can be useful for relative valuation.

0Y3M key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue51.4x
Enterprise Value/EBITDA-18.9x
PEG Ration/a

Price to Book Ratio vs Peers

How does 0Y3M's PB Ratio compare to its peers?

The above table shows the PB ratio for 0Y3M vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average5.6x
GNS Genus
2.8x32.7%UK£1.6b
PRTC PureTech Health
1.4x-20.0%UK£623.5m
OXB Oxford Biomedica
2.1x24.3%UK£425.9m
AVCT Avacta Group
15.9x-4.3%UK£292.7m
0Y3M Prothena
5.8x23.2%US$3.5b

Price-To-Book vs Peers: 0Y3M is expensive based on its Price-To-Book Ratio (5.8x) compared to the peer average (5.6x).


Price to Earnings Ratio vs Industry

How does 0Y3M's PE Ratio compare vs other companies in the GB Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.7%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.7%
n/an/an/a
No more companies

Price-To-Book vs Industry: 0Y3M is expensive based on its Price-To-Book Ratio (5.8x) compared to the UK Biotechs industry average (2.6x)


Price to Book Ratio vs Fair Ratio

What is 0Y3M's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0Y3M PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0Y3M's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 0Y3M when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0Y3M ($68.56) is trading above our estimate of fair value ($42.47)

Significantly Below Fair Value: 0Y3M is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0Y3M forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$68.56
US$92.10
+34.3%
18.7%US$120.00US$60.00n/a10
May ’24n/a
US$85.60
0%
20.0%US$120.00US$55.00n/a10
Apr ’24n/a
US$84.10
0%
21.6%US$120.00US$55.00n/a10
Mar ’24US$55.17
US$84.10
+52.4%
21.6%US$120.00US$55.00n/a10
Feb ’24US$54.27
US$84.60
+55.9%
21.0%US$120.00US$56.00n/a10
Jan ’24US$59.80
US$83.44
+39.5%
22.3%US$120.00US$55.00n/a9
Dec ’23US$61.81
US$80.89
+30.9%
23.5%US$120.00US$55.00n/a9
Nov ’23US$64.24
US$77.22
+20.2%
22.0%US$110.00US$52.00n/a9
Oct ’23US$60.70
US$73.78
+21.5%
20.6%US$110.00US$52.00n/a9
Sep ’23US$28.77
US$66.38
+130.7%
26.9%US$100.00US$45.00n/a8
Aug ’23US$31.37
US$66.88
+113.2%
26.3%US$100.00US$45.00n/a8
Jul ’23US$27.17
US$66.88
+146.2%
26.3%US$100.00US$45.00n/a8
Jun ’23US$25.27
US$66.88
+164.6%
26.3%US$100.00US$45.00n/a8
May ’23n/a
US$75.43
0%
19.2%US$100.00US$47.00n/a7
Apr ’23n/a
US$75.63
0%
17.9%US$100.00US$47.00n/a8
Mar ’23US$35.76
US$76.25
+113.2%
16.1%US$100.00US$52.00US$55.178
Feb ’23US$33.44
US$81.63
+144.1%
17.8%US$103.00US$54.00US$54.278
Jan ’23n/a
US$84.38
0%
12.6%US$103.00US$75.00US$59.808
Dec ’22US$50.73
US$84.38
+66.3%
12.6%US$103.00US$75.00US$61.818
Nov ’22US$57.02
US$86.00
+50.8%
12.9%US$103.00US$75.00US$64.247
Oct ’22US$67.56
US$80.57
+19.3%
18.6%US$103.00US$57.00US$60.707
Sep ’22US$68.59
US$70.00
+2.1%
11.9%US$82.00US$57.00US$28.777
Aug ’22US$49.99
US$69.14
+38.3%
10.6%US$76.00US$57.00US$31.377
Jul ’22US$50.96
US$60.00
+17.8%
13.2%US$75.00US$49.00US$27.178
Jun ’22US$31.08
US$33.38
+7.4%
29.7%US$45.00US$12.00US$25.278
May ’22US$27.14
US$31.14
+14.7%
29.4%US$43.00US$12.00n/a7

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies